EUR 3 million in series A for the growth and development of Cytena GmbH
Freiburg-based Cytena GmbH successfully completes another financing round. In total, two private investors and High-Tech Gründerfonds (HTGF) are investing another 3 million euros in the company. The new capital will be used to continue developing its single-cell printer lab technology, expand sales activities and tap into the potential of new applications more quickly.
The analysis of individual biological cells has rapidly gained in importance in recent years. Single cells are used in the development of modern drugs, so-called biopharmaceuticals, as well as in cancer and stem cell research. The Cytena family of single-cell printers consists of laboratory devices for handling and sorting individual viable cells. These instruments are innovative tools for the life sciences and make a long-term contribution to the development and manufacturing of new drugs.
“The technological advantage of our single-cell printers over competing products does not mean that we can rest on our laurels. Rather, our goal is to better understand and serve our customers’ needs. The new capital creates an important basis for doing so,” says Cytena CFO Benjamin Steimle. In addition, the investment will help to increase the company’s market share. Although the majority of the world’s ten largest pharmaceutical companies are already customers of the Freiburg start-up, a very large global market potential is still waiting to be tapped.
Important milestones along this path so far have included a sales cooperation with a major American company and the addition of x.sight devices to the product family. “The recent financing round enables us to accelerate the next steps in Cytena’s success story. ” says Steimle.
Dr. Lena Krzyzak, Investment Manager at HTGF, says: “With our investment in series A, we intend to continue the successful growth of our start financing. The company has developed rapidly, and we have great confidence that the management team can continue expanding the market and continue product development.“
Other news from the department business & finance
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
Last viewed contents
New biosensors for managing microbial 'workers' - Researchers at Harvard's Wyss Institute have unveiled new biosensors that enable scientists to more effectively control and 'communicate with' engineered bacteria
Helen_Keller_International
Category:French_marine_biologists
SeraCare Life Sciences sharpens focus on diagnostics industry
Disarming HIV with a "pop"
Généthon - Évry, France
Circassia Extends its Clinical-Stage Portfolio With Phase II Trials of T-Cell Vaccines Against House Dust Mite and Cat Allergies
Biotec Pharmacon reports on neuroblastoma study
Merck Serono Appoints Steven Hildemann as Global Chief Medical Officer
Macrovipera_lebetina_obtusa
Scott Fabro to Join Evolva as Chief Commercial Officer
